Vifor Licenses Isotechnika’s Lead Drug

Isotechnika Pharma has signed a global development and commercialization license agreement with Vifor Pharma Ltd., granting Vifor an exclusive license for its lead drug, voclosporin, for the treatment of lupus and all proteinuric nephrology indications. The license is for the U.S. and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong. Isotechnika is eligible to receive upfront and milestone payments, as well as royalties on commercial sales. Vifor will also purchase voclosporin capsules from Isotechnika. Financial details of the transaction were not disclosed.

“While the successful development of voclosporin for the prevention of kidney transplant rejection remains our primary focus, we believe the expansion of our platform beyond that indication via partnerships like this may help to unlock the drug’s full medical and commercial potential,” said Dr. Robert Foster, chief executive officer of Isotechnika.